# Advancing preclinical research with reconstructed in vitro skin models mimicking non-healing wounds

**Authors:** Regina Gomes Daré, Luciana B. Lopes, Alke Petri-Fink, Barbara Rothen-Rutishauser

PMC · DOI: 10.1016/j.ijpx.2026.100518 · International Journal of Pharmaceutics: X · 2026-03-17

## TL;DR

This paper reviews how 3D human skin models can better mimic chronic wounds and improve drug testing compared to animal models.

## Contribution

The paper provides a comprehensive review of advanced human skin models for chronic wound research and drug discovery.

## Key findings

- 3D skin models replicate key chronic wound features like inflammation and impaired angiogenesis.
- Human-relevant models outperform animal models in preclinical screening for wound therapeutics.
- Next-generation models integrate immune, vascular, and microbial components for better mechanistic insights.

## Abstract

Chronic skin wounds remain a significant therapeutic challenge worldwide, primarily due to persistent inflammation, impaired function of fibroblasts and keratinocytes, defective angiogenesis, and the presence of complex polymicrobial biofilms. Conventional animal models only partially capture these human-specific pathophysiological mechanisms, limiting their predictive value for pharmacological development. Recent advances in human 3D in vitro skin models, including reconstructed human epidermis, full-thickness skin equivalents, vascularized and innervated constructs, and chronic wound–derived cell systems, provide opportunities to evaluate therapeutic strategies under controlled, human-relevant conditions. Here, we critically synthesize how engineered skin platforms recreate key pathological hallmarks of non-healing wounds, including IL-1/TNF-α–driven inflammation, RAGE–NOX4-mediated oxidative stress, MMP/TIMP imbalance, fibroblast and keratinocyte senescence, impaired HIF-1α/VEGF-dependent angiogenesis, immune polarization defects, and biofilm-associated antimicrobial tolerance. We examine scaffold-based, decellularized, and bioprinted approaches that enable the incorporation of adipocytes, endothelial cells, sensory neurons, and immune compartments, enhancing the mechanistic resolution with which chronic wound biology can be interrogated. By integrating cellular, biochemical, immune, vascular, and microbial components, next-generation models allow pharmacological interrogation of targets such as IL-1/IL-1R, IL-6/STAT3, TNF-α/TNFR, RAGE–NOX4, Nrf2/KEAP1, ERK/AKT, Ang/Tie2, ferroptosis regulators, senescence pathways, and neuroimmune modulators. Collectively, these platforms bridge the gap between reductionist assays and clinical complexity, offering a rational framework for mechanism-based drug discovery and preclinical screening. This review provides guidelines for selecting and designing advanced human skin models to accelerate the development of effective therapeutics for chronic non-healing wounds.

Unlabelled Image

•Human 3D skin models reproduce the chronic wound microenvironment beyond acute injury.•Advanced skin equivalents enable mechanism-based screening of wound therapeutics.•Human-relevant models improve preclinical screening beyond conventional animal assays.•Model complexity can be tailored to specific drug development questions.•Ideal multicellular platforms integrate immune, vascular, neural and microbial components.

Human 3D skin models reproduce the chronic wound microenvironment beyond acute injury.

Advanced skin equivalents enable mechanism-based screening of wound therapeutics.

Human-relevant models improve preclinical screening beyond conventional animal assays.

Model complexity can be tailored to specific drug development questions.

Ideal multicellular platforms integrate immune, vascular, neural and microbial components.

## Linked entities

- **Genes:** IL1A (interleukin 1 alpha) [NCBI Gene 3552], TNF (tumor necrosis factor) [NCBI Gene 7124], AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177], NOX4 (NADPH oxidase 4) [NCBI Gene 50507], MMP (Muscle moisture percentage) [NCBI Gene 449383], TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554], IL6 (interleukin 6) [NCBI Gene 3569], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132], GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817], EPHB2 (EPH receptor B2) [NCBI Gene 2048], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], ANG (angiogenin) [NCBI Gene 283], TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010]

## Full-text entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010] {aka CD202B, GLC3E, TIE-2, TIE2, VMCM, VMCM1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, ANG (angiogenin) [NCBI Gene 283] {aka ALS9, HEL168, RAA1, RNASE4, RNASE5}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, NOX4 (NADPH oxidase 4) [NCBI Gene 50507] {aka KOX, KOX-1, RENOX}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}
- **Diseases:** inflammation (MESH:D007249), skin wounds (MESH:D014947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13022694/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13022694/full.md

## References

192 references — full list in the complete paper: https://tomesphere.com/paper/PMC13022694/full.md

---
Source: https://tomesphere.com/paper/PMC13022694